Dantrolene has no effect on [3H]-ryanodine binding

Pharmacology Reviews and Communications

Volumn 10, Issue 3, 1999, Pages 221-226

  Noël, François ^a   Maloteaux, Jean Marie ^b  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Dantrolene; Malignant hyperthermia; Neuroleptic malignant syndrome; Rat; Ryanodine

Indexed keywords

CALCIUM CHANNEL; DANTROLENE; RYANODINE; RYANODINE RECEPTOR;

ANIMAL TISSUE; ARTICLE; BINDING SITE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; HEART VENTRICLE; MALE; MEMBRANE BINDING; NONHUMAN; PRIORITY JOURNAL; RAT; SOLEUS MUSCLE;

EID: 0032766853     PISSN: 10288945     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. 3H]PN200-110 binding to porcine skeletal muscle dihydropyridine receptors. Biochem. Biophys. Res. Commun., 187, 894-900.
2. Ellis K.O., Butterfield J.L., Wessels F.L. and Carpenter J.F. (1976). A comparison of skeletal, cardiac, and smooth muscle actions of dantrolene sodium - a skeletal muscle relaxant. Arch. Int. Pharmacodyn., 224, 118-132.
3. Flewellen E.H., Nelson T.E., Jones W.P., Arens J.F. and Wagner D.L. (1983). Dantrolene dose response in awake man: implications for management of malignant hyperthermia. Anesthesiology, 59, 275-280.
4. Fratea S., Langeron O., Lecarpentier Y., Coriat P. and Riou B. (1997). In vitro effects of dantrolene on rat myocardium. Anesthesiology, 86, 205-215.
5. 2+ release by direct and specific action at skeletal muscle ryanodine receptors. J. Biol. Chem., 272, 26965-26971.
6. Hakamata Y., Nakai J., Takeshima H. and Imoto K. (1992). Primary structure and distribution of a novel ryanodine receptor/calcium release channel from rabbit brain. FEBS lett., 312, 229-235.
7. 2+ release channels in longitudinal muscle of intestine. Am. J. Physiol, 266, C1421-C1431.
8. Lietman P.S., Haslam R.H.A. and Walcher J.R. (1974). Pharmacology of dantrolene sodium in children. Arch. Phys. Med. Rehabil, 55, 388-392
9. 2+ release channels and their regulation by endogenous effector Annu. Rev. Physiol., 56, 485-508.
10. Nelson I.E., Lin M., Zapata-Sudo G. and Sudo R.T. (1996). Dantrolene sodium can increase orattenuate activity of skeletal muscle ryanodine receptor calcium release channel. Anesthesiology, 84, 1368-1379.
11. 2+ release from sarcoplasmic reticulum in guinea pig skeletal muscle. Eur. J. Pharmacol., 178, 11-19.
12. Palnitkar S.S., Mickelson J.R., Louis C.F. and Parness J. (1997). Pharmacological distinction between dantrolene and ryanodine binding sites evidence from normal and malignant hypertermia-susceptible porcine skeletal muscle. Biochem. J., 326, 847-852.
13. Parness J. and Palnitkar S.S. (1995). Identification of dantrolene binding sites in porcine skeletal muscle sarcoplasmic reticulum. J. Biol. Chem., 270, 18465-18472.
14. Pessah I.N., Lynch C. and Gronert G.A (1996). Complex pharmacology of malignant hyperthermia. Anesthesiology, 84, 1275-1277.
15. Pessah I.N., Francini A.O, Scales D.J., Waterhouse A.L. and Casida J E. (1986). Calcium-ryanodine receptor complex - solubilization and partial characterization from skeletal muscle junctional sarcoplasmic reticulum vesicles J. Biol Chem., 261, 8643-8648.
16. Rosa R., Sanfeliu C., Rodríguez-Farré E., Frandsen A., Schousboe A. and Suñol C. (1997). Properties of ryanodine receptors in cultured cerebellar granule neurons: effects of hexachlorocyclohexane isomers and calcium. J. Neurosci. Res., 47, 27-33.
17. Shoshan-Barmatz V., Pressley T.A., Higham S. and Kraus-Friedmann N. (1991). Characterization of high-affinity ryanodine-binding sites of rat liver endoplasmic reticulum. Biochem. J., 276, 41-46.
18. Smith S.M. and Nahorski S.R. (1993). Characterization and distribution of inositol phosphate and ryanodine receptors in the rat brain. J. Neurochem., 60, 1605-1614.
19. Sorrentino V. (1995). The ryanodine receptor family of intracellular calcium release channels. Adv. Pharmacol., 33, 67-90.
20. Ward A, Chaffman M.O. and Sorkin E.M. (1986). Dantrolene - a review of its pharmacodynamic and pharmacokinetic properties and therapeurtic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spasticity. Drugs, 32, 130-168.